An interventional study of Hemoglobin A1c Lab Result Communication Tool in Prediabetes, Health Communication and Patient Comprehension, sponsored by University of California, Los Angeles. Recruiting at 1 site in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-07-09.
Sponsored by University of California, Los Angeles · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 390 studies in Prediabetic State with a site in United States — 83 open to participants now, 107 under way, 2 of them phase 3. Prediabetic State · United States.
Among the 390 studies in Prediabetic State with a site in United States, this one is the 12th largest by planned enrollment of the 362 interventional ones that give a count, is one of 39 that started in 2026, is one of 288 with no phase, reaches primary completion later than 22 of the 106 other live ones, and was the 345th registered.
919 studies on the registry are indexed under Prediabetic State; 231 are open to participants now.
Browse Prediabetic State studies →83 of the 390 studies in Prediabetic State with a site in United States are open now. Recruiting first, the newest first:
Rahul Sachdeva · Sites in United States
Ages 18+ · Healthy volunteers
University of South Florida · Sites in United States
Ages 18–70
St. Louis University · Sites in United States
Ages 18–69
Morehouse School of Medicine · Sites in United States
Ages 12+ · Healthy volunteers
Penn State University · Sites in United States
Ages 25–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 144 Prediabetic State studies recruiting now, 51 (35%) set no upper age limit and 83 (58%) stop at 75 or younger; 12 take children under 18; 54 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
390 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 25 · Phase 3 16 · Phase 4 16
First in 1996; this study’s year is marked. 39 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,200 is above the median of 62 across 763 interventional studies indexed under Prediabetic State.
Median enrollment 54 across the 362 interventional studies, 188 across the 28 observational. Of the 258 that completed or were terminated, 90 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 390 have an industry lead sponsor. The 10 most frequent:
University of California, Los Angeles is the lead sponsor of 1,172 studies on the registry; 195 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 70 (74%) have results posted.
University of California, Los Angeles has 8 studies filed under Prediabetic State — fewer than ten, so there is no comparison to draw.
46 of the studies in Prediabetic State with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06995378University of California, Los AngelesStudy EHR Risk Stratification Tools | 2026-11 |
| NCT05165706Stanford UniversityLongitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance | 2026-11-30 |
| NCT07450118University of DelawareNested Pilot Study Comparing Two Treatments to Reduce Type 2 Diabetes Risk in At-Risk Delawareans | 2026-12 |
| NCT05067621Yale UniversitySemaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | 2026-12 |
| NCT07868432Tufts UniversityGlycemic Impact of NNS Via the Gut Microbiome | 2026-12 |
Add all 46 to your calendar (.ics) → With an account.
Among the 390 studies in Prediabetic State with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates whether adding machine learning-based risk information to electronic health record (EHR) lab result messages helps older adults better understand their risk of developing diabetes and influences their emotional responses, quality of life, and healthcare use.
Eligible participants are adults aged 65 years and older with a UCLA primary care provider and a hemoglobin A1c level in the range (5.7-6.0%). Participants are identified automatically at the time their lab results are processed and are randomly assigned to receive either standard lab result messages or modified messages that include a "very low risk" label generated by a machine learning model.
All participants who are randomized are invited to complete two surveys: one shortly after their lab result is posted in MyChart and a follow-up survey approximately 30 days later. The study also uses de-identified EHR data to examine patterns of healthcare utilization and progression to diabetes. Provider comments related to lab result messaging will be analyzed to explore differences in response patterns between the two groups.
Prediabetes thresholds based on hemoglobin A1c were originally developed using younger, healthier populations and may not reflect the slower and more variable glycemic changes observed in older adults. Evidence from large community-based cohorts suggests that adults aged 65 years and older with A1c values in the prediabetes range are often more likely to return to normal glycemia than to progress to diabetes, creating uncertainty for patients and providers when interpreting lab results.
Machine learning models developed using de-identified UCLA Health EHR data from multiple annual cohorts between 2020 and 2024 demonstrated strong performance in predicting progression to diabetes. The final model uses a CatBoost architecture and incorporates approximately 94 routinely collected clinical variables to generate patient-specific risk scores. Model performance was evaluated across yearly cohorts, and the selected model is locked for the duration of the study without updating or adapting to new data.
The study follows a real-world, randomized deployment design in which eligible individuals in the lowest 15% of model-predicted risk within the eligible study population are identified automatically at the time lab results are processed and assigned to either modified or standard lab result messaging. De-identified EHR data and free-text provider comments are used to examine healthcare utilization, disease progression, and provider response patterns over time.
All participants who are randomized are invited to complete two surveys. The first survey is administered shortly after receipt of the laboratory result and is designed to assess immediate patient understanding of the result and emotional responses such as anxiety or reassurance. A second survey is administered approximately one month later and uses validated instruments to measure health-related quality of life, food-related quality of life and eating behavior, and perceived burden of healthcare. Both study arms receive the same surveys, allowing comparison of patient-reported outcomes between standard and modified laboratory result messaging. Surveys are distributed only to participants who have been randomized to either modified or standard laboratory result messaging. Therefore, no additional eligibility criteria apply for survey participation beyond randomization.
By embedding model-generated risk information directly into routine EHR workflows, this study aims to generate evidence on whether precision-based communication can support more individualized, patient-centered care and inform future implementation across broader patient populations and clinical use cases.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All randomized participants are eligible to receive study surveys. No additional eligibility criteria apply for survey participation.
HgbA1c of 6.0 or above is not eligible.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive modified electronic health record (EHR) lab result communications in the patient portal (MyChart) and provider-facing EHR interface that include a qualitative "very low risk" label generated by a machine learning-based tool, along with brief explanatory text providing context about their current results and indicating a low level of concern at this time.
Device: Hemoglobin A1c Lab Result Communication Tool
Participants receive standard electronic health record (EHR) lab result communications without any machine learning-generated risk labeling or explanatory text providing additional context about level of concern.
A behavioral intervention delivered through a personalized Electronic Health Record (EHR)-integrated lab result communication tool designed to improve emotional and cognitive responses to lab results among adults aged 65+. The tool applies behavioral science principles such as risk personalization, simplified messaging, and visual framing to reduce patient anxiety, enhance understanding, and support informed decision-making.
Prediabetes- Related Healthcare Utilization
Total count of prediabetes-related healthcare utilization defined as the sum of outpatient visits to endocrinology, repeat hemoglobin A1c tests, and new prescriptions for diabetes-related medications following the index A1c result.
Time frame: 365 days after result
Number of Repeat Hemoglobin A1c Tests
Total number of repeat hemoglobin A1c laboratory tests performed after the index test. This measure reflects follow-up glycemic testing and serves as an indicator of diabetes-related monitoring and healthcare utilization.
Time frame: 365 days after result
Number of Prescriptions for Diabetes-Related Medications
Total number of prescriptions issued for medications commonly used for glycemic management (e.g., metformin) following the index hemoglobin A1c result. This outcome captures initiation of pharmacologic treatment related to diabetes risk.
Time frame: 180 days after result
Total Number of Outpatient Healthcare
Total count of outpatient visits across all specialties following the index A1c result
Time frame: 180 days after result
Numbers of Referrals to Endocrinology
Total number of outpatient referrals to an endocrinologist occurring after the index hemoglobin A1c laboratory result. This measure is used to quantify diabetes-related specialty care utilization potentially associated with interpretation of the laboratory result communication.
Time frame: 14 days after initial result
Number of Referrals to Nutrition Services
Number of participants with an electronic referral order placed to clinical nutrition services documented in the electronic health record after release of the hemoglobin A1c result.
Time frame: 14 days after initial result
Number of Referrals to Diabetes Education
Number of participants with an electronic referral order placed to diabetes education services documented in the electronic health record after release of the hemoglobin A1c result.
Time frame: 14 days after initial result
Number of Completed Endocrinology Visit
Number of participants who complete an outpatient endocrinology encounter documented in the electronic health record after laboratory result notification. Visit completion will be identified using encounter records associated with endocrinology clinic services.
Time frame: 180 days after result
Completed Nutrition Services Visit
Number of participants who complete an outpatient visit with clinical nutrition services documented in the electronic health record following laboratory result notification. Completion will be determined using encounter data associated with nutrition services.
Time frame: 180 days after result
Completed Appointments to Diabetes Education
Number of participants who complete an outpatient visit with diabetes education services documented in the electronic health record following laboratory result notification. Completion will be determined using encounter data associated with diabetes education.
Time frame: 180 days after result
Number of Patient MyChart Messages
Count of MyChart Test Result Messages
Time frame: 7 days after viewing lab result
Numbers of Phone Calls Received after A1c Results
Count of telephone encounters to ordering provider
Time frame: 7 days after viewing lab result
Self-Reported Quality of Life
Patient-reported quality of life assessed using survey responses evaluating overall physical, mental, and health-related well-being following receipt of lab result communication.
Time frame: 30 days after initial survey invitation
Self-Reported Physical Function Following Lab Result
Self-reported physical function asking about ability to perform activities such as household chores, stair climbing, walking, and running errands following receipt of lab result communication. This measure uses structured survey items to evaluate whether receipt of A1c lab result communication is associated with changes in exercise.
Time frame: 30 days after initial survey invitation
Self-Reported Dietary Behaviors Following Lab Result
Patient-reported dietary behaviors following receipt of lab result, including eating patterns, appetite, satiety, and food-related changes or restrictions due to concerns about lab results. These behaviors are assessed to understand potential impacts on health and weight-related decision-making. This measure uses structured survey items to evaluates whether receipt of A1c lab result communication is associated with changes dietary behaviors.
Time frame: 30 days after initial survey invitation
Patient Understanding and Anxiety Related to Lab Result Communication
Patient-reported understanding of lab report and emotional response to result communication, including perceived clarity, reassurance, and level of concern, assessed using structured survey items designed to measure comprehension and anxiety following receipt of laboratory result messaging.
Time frame: 7 days after results
Number of Incidence of Diabetes
Proportion of participants who progress from prediabetes to diabetes based on electronic health record data, defined by meeting diagnostic criteria for diabetes during follow-up. This outcome is included to monitor long-term clinical safety and progression.
Time frame: 3 years
Plan to share: No
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Nov 2026, 6 months after the start.
Of 379 non-industry interventional studies with no phase under Prediabetic State, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 38. This study's planned 6 months is below that.
Counting every sponsor, half of 425 studies reached it within 23 months; a quarter within 11 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, Los Angeles →